Home/Pipeline/lomonitinib

lomonitinib

Acute Myeloid Leukemia (AML)

IND-EnablingActive

Key Facts

Indication

Acute Myeloid Leukemia (AML)

Phase

IND-Enabling

Status

Active

Company

Lomond Therapeutics

About Lomond Therapeutics

Lomond Therapeutics is a Boston-based, private, precision hematology company founded in 2021. It is developing a pipeline of small molecule drugs designed to overcome treatment resistance in hematological cancers, with a lead program targeting FLT3/IRAK4 in Acute Myeloid Leukemia (AML). The company's strategy centers on creating 'pan-variant' therapies that inhibit multiple resistance mutations and escape mechanisms simultaneously, aiming to address a critical unmet need in oncology. Leadership includes experienced biotech executives and is backed by venture capital firms like OrbiMed and Teal Ventures.

View full company profile

Therapeutic Areas

Oncology Hematology

Other Acute Myeloid Leukemia (AML) Drugs

Drug	Company	Phase	Status
Mipletamig (APVO436)	Aptevo Therapeutics	Phase 1/2	Active
lonitoclax	Lomond Therapeutics	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Discovery	Active
AB8939	AB Science	Phase 1	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 1	Active
NC525	NextCure	Preclinical	Active
ACD-101	Advanced Cellular Dynamics	Phase 1	IND-Enabling
ABD-3001	Advanced Biodesign	Phase 1	Active (trial began early 2023)
HC-7366	HiberCell	Phase 1b	Active - Monotherapy & in combination with venetoclax and azacitidine
Prexigebersen (BP1001)	Bio-Path Holdings	Phase 2	Active
oNKord® (Inaleucel)	Glycostem	Phase 1/2a	Active